DOI:

Impact of post-procedural aortic regurgitation on mortality after TAVI

Hayashida K., Lefèvre T., Chevalier B., Hovasse T., Romano M., Garot P., Watanabe Y., Bouvier E., Farge A., Donzeau-Gouge P., Cormier B., Morice M-C

Treatment and consequences of regurgitation during transcatheter valve therapies

Impact of post-procedural aortic regurgitation on mortality after TAVI

Aims: Post-procedural aortic regurgitation (post-AR) is known to be associated with poor short-term to mid-term outcome after transcatheter aortic valve implantation (TAVI). The aim of this study was to clarify the impact of mild post-AR on clinical outcomes.

Methods and results: We compared clinical outcomes in 400 consecutive TAVI recipients according to post-AR grade: none (group 1=74.8%), mild (group 2=22.2%) or moderate to severe (group 3=3.0%). The mean age was similar in the three groups (83.4±6.1 years) as well as logistic EuroSCORE (22.5±11.4, 24.5±11.6 and 21.5±9.4%, p=0.28) and annulus size (22.0±1.8, 22.2±2.1 and 22.5±2.1 mm, p=0.53). The Edwards valve was the most frequently used in group 1 compared to groups 2 and 3 (89.3, 78.7 and 83.3%, p=0.03) and the implanted valve size was similar in all groups (25.6±2.0, 25.4±2.2 and 25.5±2.2 mm, respectively, p=0.69). Post-dilatation was required more frequently in group 3 (4.7, 24.1 and 50.0% respectively, p<0.01). Post-procedural increase in mitral regurgitation was in line with the post-AR grade (0.78±0.73, 1.22±0.80 and 1.89±0.78, respectively, p<0.01). Despite the absence of difference in 30-day mortality, longer-term outcome was significantly poorer in patients with mild AR than in those with no AR (log-rank p<0.01), albeit better than in patients with moderate to severe AR regardless of TAVI type and left ventricular function. In group 2 (mild, post-AR), patients with no pre-procedural AR had worse outcome compared to those who had pre-procedural AR (log-rank p=0.01). Post-AR was also identified as an independent predictor of mid-term to long-term mortality (HR1.68, 95% CI: 1.21-1.44, p<0.01).

Conclusions: Mild AR post TAVI is associated with a worse outcome when compared to no AR. Careful valve selection and post-dilatation when required to avoid mild post-AR might contribute to improved clinical outcome after TAVI.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

Suggested by Cory

Clinical Research

10.4244/EIJ-D-21-00784 May 15, 2022
Five-year outcomes of mild paravalvular regurgitation after transcatheter aortic valve implantation
Okuno T et al
free

10.4244/EIJV11I10A220 Feb 19, 2016
Accurate procedural assessment of AR – critical for successful TAVI
Kapadia S and Tuzcu ME
free

10.4244/EIJV8SQA7 Sep 30, 2012
Prognostic impact of aortic regurgitation after transcatheter aortic valve implantation
Jilaihawi H and Makkar R
free

10.4244/EIJV8SQA8 Sep 30, 2012
Treatment and prevention of aortic regurgitation after transcatheter aortic valve implantation
Hayashida K and Lefèvre T
free
Trending articles
310.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
172.13

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76.25

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
35

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved